- cafead   Oct 18, 2021 at 11:02: PM
via The U.S. Food and Drug Administration declined to approve United Therapeutics and MannKind Corp's lung disease therapy, citing an inspection issue at a third-party facility, the companies said on Monday.
The therapy is a drug-device combination that uses United Therapeutics' approved treatment, Tyvaso, in combination with MannKind's portable inhaler.
article source
The therapy is a drug-device combination that uses United Therapeutics' approved treatment, Tyvaso, in combination with MannKind's portable inhaler.
article source